Type of information: IPO
Company: Y-mAbs Therapeutics (USA - NY)
Funding type: IPO
- • On September 20, 2018, Y-mAbs Therapeutics, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $96 million, before underwriting discounts and commissions and estimated offering expenses payable by the company. All shares are being offered by the company.
- In addition, Y-mAbs Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The company’s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “YMAB” on Friday, September 21, 2018. The offering is expected to close on Tuesday, September 25, 2018, subject to customary closing conditions.
- BofA Merrill Lynch and Cowen are acting as joint book-running managers for the offering. Canaccord Genuity is acting as lead manager for the offering and BTIG is acting as co-manager for the offering.
Therapeutic area: Cancer - Oncology